Type 2 immunopathology is a cardinal feature of allergic diseases, and involves cooperation between adaptive immunity and innate effector responses. Virtually all cell types relevant to this pathology generate leukotriene and/or prostaglandin mediators that derive from arachidonic acid, and/or express receptors for such mediators. Recent studies highlight prominent functions for these mediators in communication between innate and adaptive immune systems, as well as amplification or suppression of type 2 effector responses. This review focuses on recent advances and insights, and highlights existing and potential therapeutic applications of drugs that target these mediators or their receptors, with a special emphasis on their regulation of the innate and adaptive lymphocytes relevant to type 2 immunopathology.

2型免疫病理学是过敏性疾病的主要特征，涉及适应性免疫和先天性效应反应之间的合作。实际上，与该病理学有关的所有细胞类型均产生源自花生四烯酸的白三烯和/或前列腺素介体，和/或表达此类介体的受体。最近的研究强调了这些介体在先天性和适应性免疫系统之间的交流中的重要功能，以及对2型效应子反应的放大或抑制。这篇综述着重于最近的进展和见解，并着重介绍了针对这些介体或其受体的药物的现有和潜在治疗应用，特别着重于它们对与2型免疫病理学相关的先天性和适应性淋巴细胞的调节。